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Introduction: Activated fibroblast-like synoviocytes (FLSs) in rheumatoid arthritis (RA) share many characteristics
with tumour cells and are key mediators of synovial tissue transformation and joint destruction. The glycoprotein
podoplanin is upregulated in the invasive front of several human cancers and has been associated with epithelial-
mesenchymal transition, increased cell migration and tissue invasion. The aim of this study was to investigate
whether podoplanin is expressed in areas of synovial transformation in RA and especially in promigratory RA-FLS.
Methods: Podoplanin expression in human synovial tissue from 18 RA patients and nine osteoarthritis (OA)
patients was assessed by immunohistochemistry and confirmed by Western blot analysis. The expression was
related to markers of synoviocytes and myofibroblasts detected by using confocal immunofluoresence microscopy.
Expression of podoplanin, with or without the addition of proinflammatory cytokines and growth factors, in
primary human FLS was evaluated by using flow cytometry.
Results: Podoplanin was highly expressed in cadherin-11-positive cells throughout the synovial lining layer in RA.
The expression was most pronounced in areas with lining layer hyperplasia and high matrix metalloproteinase 9
expression, where it coincided with upregulation of a-smooth muscle actin (a-sma). The synovium in OA was
predominantly podoplanin-negative. Podoplanin was expressed in 50% of cultured primary FLSs, and the
expression was increased by interleukin 1b, tumour necrosis factor a and transforming growth factor b receptor 1.
Conclusions: Here we show that podoplanin is highly expressed in FLSs of the invading synovial tissue in RA. The
concomitant upregulation of a-sma and podoplanin in a subpopulation of FLSs indicates a myofibroblast
phenotype. Proinflammatory mediators increased the podoplanin expression in cultured RA-FLS. We conclude that
podoplanin might be involved in the synovial tissue transformation and increased migratory potential of activated
FLSs in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease predominantly affecting joints, leading to
tissue destruction and functional disability [1,2]. Both
genetic and environmental factors are believed to contri-
bute to the dysregulated immune responses seen in this
heterogeneous autoimmune disease [3]. Today, treatment
strategies involve traditional disease-modifying antirheu-
matic drugs as well as biologic agents targeting proin-
flammatory cytokines (tumour necrosis factor a (TNFa),
interleukin (IL)-1 and IL-6), B cells or the activation of T
cells [4]. Despite this arsenal of drugs, at least 30% of the
patients are resistant to the available therapies, suggesting
that yet other mediators must be important.
The most prominent feature of RA is the progressive
destruction of articular cartilage and bone, which is
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any medium, provided the original work is properly cited.orchestrated by activated RA fibroblast-like synoviocytes
(RA-FLSs) [5,6]. RA-FLSs not only mediate tissue
destruction but also are considered to play a major role
in initiating and driving RA in concert with inflamma-
tory cells [7]. In the healthy synovium, one to three
layers of synoviocytes, the macrophage-like type A and
the more abundant fibroblast-like type B (also referred
to as synovial fibroblast), form the synovial lining layer
separating the synovial sublining layer of loose connec-
tive tissue from the joint cavity [8,9]. The synoviocytes
are interconnected with adherens junctions containing
cadherin-11 [10,11] and E-cadherin [12,13] and are
embedded in a lattice of extracellular matrix (ECM)
resembling an epithelium but lacking a discrete basal
membrane as well as gap junctions and desmosomes.
Apart from being a marker of FLSs, cadherin-11 has
been shown to be essential for the formation of synovial
lining structures in vitro and for the development of
inflammatory arthritis in mice [14,15].
The morphological hallmarks of RA include activation
of FLSs; infiltration of inflammatory cells such as T
cells, B cells and macrophages in the sublining; hyper-
plasia of the synovial lining layer; fibrotic deposition;
and subsequent formation of the “pannus” [16]. This tis-
sue mass expands and attaches to and invades the adja-
cent cartilage and subchondral bone [17]. The major
cell type accounting for the thickened lining layer as
well as for pannus formation is believed to be activated
FLSs [18,19]. These aggressive cells share many charac-
teristics with tumour cells, with upregulated expression
of proto-oncogenes and promigratory adhesion mole-
cules, increased production of proinflammatory cyto-
kines and matrix-degrading enzymes [7], as well as
increased resistance to apoptosis [20,21]. There are data
indicating that the transformed phenotype of RA-FLS is
stable and maintained even in the absence of stimulus
from inflammatory cells [22]. In high-inflammation
synovial tissue, RA-FLSs show a gene expression profile
characteristic of myofibroblasts, and cells of the synovial
lining in RA have been found to express a-smooth mus-
cle actin (a-sma) and type IV collagen [13,23]. Thus, it
has been suggested that RA-FLSs can undergo a process
resembling epithelial-mesenchymal transition (EMT), a
phenomenon known from early developmental pro-
cesses, tissue repair, fibrosis and carcinogenesis [24,25].
Recently, it was also suggested that migrating RA-FLSs
might be responsible for spreading the disease to distant
joints [26].
Podoplanin (identical to human PA2.26, aggrus and
T1a-2), is a small, 38- to 40-kDa, mucin-type trans-
membrane glycoprotein normally expressed on human
lymphatic endothelia, basal epithelial keratinocytes,
myoepithelial cells and myofibroblasts of certain glandu-
lar tissues, follicular dendritic cells and fibroblastic
reticular cells of lymphoid organs and alveolar type I
cells [27,28]. We demonstrated strong podoplanin
expression on subepithelial interstitial cells in human
endolymphatic tissue of the inner ear [29]. The physio-
logic function of podoplanin is to a large extent
unknown, but knockout (KO) studies showed that it is
crucial for the development of the lung and deep lym-
phatics in mice [28]. The podoplanin-KO mice died at
birth as a result of respiratory failure and generalised
lymphoedema. Overexpression of this glycoprotein in
epithelial cells induced a dentritic cell morphology and
increased cell adhesion and migration [27]. Interestingly,
increasing data show that podoplanin is upregulated on
the invasive front of human cancers [27,30]. The expres-
sion of podoplanin is correlated with metastasis and a
bad prognosis. In addition, podoplanin (or aggrus)
induces platelet aggregation of tumour cells [31] and
has been associated with both EMT-dependent and
EMT-independent tumour cell invasion [32]. There are
a few studies indicating increased podoplanin expression
in fibroblasts in reactive tissues, such as in chronic
pleuritis, in cancer-associated fibroblasts [33] and in cul-
tured fibroblasts [34]. However, little is known about
the potential role of podoplanin in inflammation and tis-
sue repair. In this study, we were interested to see
whether podoplanin is expressed in FLSs in RA and
could be associated with the fibrotic transformation of
the synovium in this disease.
Materials and methods
Human synovial tissue and cells
Synovial tissue specimens and fluid were obtained from
patients with RA (n = 18) or OA (n =9 )d u r i n gj o i n t
replacement surgery or therapeutic joint aspiration at
Sahlgrenska University Hospital and Spenshult Hospital
in Sweden. Both weight-bearing (knee and hip) and
non-weight-bearing (shoulder and elbow) joint speci-
mens were included. All RA patients fulfilled the Ameri-
can College of Rheumatology 1987 revised criteria for
RA [35]. Preoperative radiographs were scored accord-
ing to Larsen index (1 to 5) [36]: 0 = normal; 1 = slight
abnormality, soft tissue swelling, periarticular osteoporo-
sis and slight joint space narrowing; 2 = early abnormal-
ity, erosions (obligatory in non-weight-bearing joints)
and joint space narrowing; 3 = medium destructive
abnormality, erosions and joint space narrowing; 4 =
severe destructive abnormality, erosions, joint space nar-
rowing and bone deformation; and 5 = mutilating
abnormality. The patient characteristics are outlined in
Table 1. All patients gave informed consent, and the
procedure was approved by the Ethics Committee of
Gothenburg in Sweden. Human primary FLS cultures
were established as follows: representative tissue pieces
were minced, treated with 1 mg/ml collagenase/dispase
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passaged through a cell strainer. The cell suspension
was rinsed twice in phosphate-buffered saline (PBS),
resuspended in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) GlutaMAX (Invitrogen, Camarillo, CA, USA)
supplemented with 10% heat-inactivated foetal bovine
serum (HIFBS) (Sigma, St. Louis, MO, USA), 50 μg/ml
gentamicin (Sanofi-Aventis, Paris, France) and 100 μg/
ml normocin (Invivogen, San Diego, CA, USA) and
i n c u b a t e da t5 %C O 2 at 37°C. Cells in passages 3
through 6 were used.
Immunohistochemistry
Paraformaldehyde (PFA)-fixed (Histolab, Göteborg, Swe-
den), paraffin-embedded (4 μm) or acetone-fixed (Histo-
lab) frozen sections (6 μm) were rehydrated in Tris-
buffered saline for 10 minutes. Antigen retrieval was
performed when required in a pressure chamber (2100
Retriever; Histolab). Unspecific binding was blocked
using serum-free protein block or normal rabbit serum
(Dako, Glostrup, Denmark). After incubation with
mouse monoclonal antihuman podoplanin (clone D2-40;
AbD Serotec, Oxford, UK), mouse monoclonal antihu-
man cadherin-11 (clone 5B2H5; Invitrogen) or mouse
monoclonal antihuman CD90 antibodies (clone AS02;
Dianova, Hamburg, Germany), respectively, the speci-
mens were incubated with a biotinylated rabbit anti-
mouse immunoglobulin G F(ab’)2 fragment (Dako)
followed by streptavidin-conjugated alkaline phosphatase
(Dako). Fast Red Naphthol (Sigma) was used as a sub-
strate, and the specimens were counterstained with
Mayer’s haematoxylin (Histolab) and mounted in Aqua-
Mount mounting medium (VWR International Ltd, Lei-
cestershire, UK). The same staining protocol was used
for immunocytochemistry of primary FLS seeded onto
chamber slides (Lab-Tek; Nunc, Rochester, NY, USA)
and fixed in PFA. Normal mouse IgG1 (Dako) was used
as a negative control. The podoplanin staining was
scored by two independent observers blinded to the
procedure according to the following scoring method: 0
= negative staining, 1 = positive staining of single or
limited groups of cells in the lining layer, 2 = continu-
ous positive staining of the cells of the synovial lining
layer and 3 = same as 2, but with the addition of posi-
tive staining of cells in the sublining layer.
Immunofluorescence and confocal microscopy
Paraffin-embedded synovial sections were subjected to a
double-staining procedure: incubation with rabbit anti-
human cadherin-11 (Invitrogen), rabbit anti-matrix
metalloproteinase (MMP)-9 (AB805; Millipore, Billerica,
MA, USA), rabbit antihuman E-cadherin (clone H-108;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
rabbit anti-a-sma (PA1-37024; Thermo Scientific, Rock-
ford, IL, USA) antibodies followed by addition of Alexa
Fluor 555-conjugated goat antirabbit IgG (Invitrogen)
or, in one step, Alexa Fluor 647-conjugated mouse anti-
human CD68 (clone KP1; Santa Cruz Biotechnology).
Second, mouse antihuman podoplanin (clone D2-40)
incubation was followed by Alexa Fluor 488-conjugated
goat antimouse IgG (Invitrogen). Alternatively, biotiny-
lated mouse antihuman podoplanin (Acris Antibodies
GmbH, Herford, Germany) and Alexa Fluor 488-
conjugated streptavidin were added prior to mouse
antihuman cadherin-11 (clone 5B2H5) and Alexa Fluor
555-conjugated goat antimouse IgG (Invitrogen). Slides
were placed in ProLong Gold antifade reagent mounting
medium with 4’,6-diamidino-2-phenylindole (Invitro-
gen). Normal mouse IgG1 or normal rabbit serum
(Dako) was used as negative controls. Images were col-
lected using a confocal microscope (LSM700; Zeiss,
Oberkochen, Germany). The background fluorescence
level was set with the negative controls, and images
were analysed using Zen image analysis software 2009
(Zeiss).
Western blot analysis
Membrane proteins from tissue and cell pellets were
prepared by sodium carbonate treatment [37]. In brief,
lyophilized material was resuspended in 0.1 M sodium
carbonate before sonication. After removal of cell debris,
the membrane fraction was collected by ultracentrifuga-
tion at 115,000 g for 75 minutes. The membrane pro-
teins were solubilised with 7 M urea, 2 M thiourea, 40
mM Tris, 1% C7 detergent (wt/vol) and 4% 3-[(3-chola-
midopropyl)dimethylammonio]-1-propanesulfonate buf-
fer (wt/vol) and kept at -80°C before use.
Samples, together with recombinant unglycosylated
human podoplanin core protein (ProSpec, Ness-Ziona,
Israel), were separated by 20% sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions with 10 mM dithiothreitol. After
being transferred onto polyvinylidene fluoride membrane,
Table 1 Characteristics of patients
a
Characteristic RA (n = 18) OA (n =9 )
Age, mean yr 61.8 68.4
Sex, F/M 13/6 6/3
Disease duration, mean yr 21.9 -
Seropositive
b, % 82% -
Larsen score
c (mean ± SD) 2.9 ± 0.6 -
DMARDs, % 72% -
Steroids, % 44% -
Biologic drugs, % 33% -
aRA, rheumatoid arthritis; OA, osteoarthritis; DMARDs, disease-modifying
antirheumatic drugs;
brheumatoid factor or anticyclic citrullinated peptide
antibody-positive;
cLarsen index score (1 to 5) of the biopsied joint (bone
erosion present if index >1).
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(1:50; D2-40) and detected with a horseradish peroxidise-
conjugated rabbit antimouse antibody (1:2,000; DakoCyto-
mation) and chemiluminescence (SuperSignal West Femto
Maximum Sensitivity Substrate; Thermo Scientific).
Flow cytometry
Primary synovial cell cultures from patients with RA (n
= 6) and patients with OA (n = 5) were trypsinised,
resuspended in fluorescence-activated cell sorting buffer
(5% HIFBS, 0.09% sodium azide and 0.5% ethylenedia-
minetetraacetic acid in PBS) and transferred onto a 96-
well plate. For intracellular staining (CD68; a-sma), cells
were PFA-fixed and permeabilised with 0.1% Triton X-
100 in PBS. Unspecific binding was blocked using 1%
HIFBS in PBS or Beriglobin P (human IgG; Apoteket,
Sweden). Staining was performed with allophycocyanin
(APC)-conjugated mouse antihuman CD90, phycoery-
thrin (PE)-conjugated mouse antihuman CD68, PE-con-
jugated mouse antihuman CD29 (BD Biosciences, San
Jose, CA, USA), mouse antihuman podoplanin (clone
D2-40), mouse antihuman cadherin-11 (clone 5B2H5),
rabbit antihuman a-sma (PA1-37024) and isotype con-
trols (BD Biosciences). The unconjugated antibodies
were incubated with secondary PE-conjugated rat anti-
mouse IgG1 (BD Biosciences) or APC-conjugated goat
antirabbit IgG (Santa Cruz Biotechnology) in a second
step. Fluorescence was measured using the FACSCanto
II system (BD Biosciences) equipped with DIVA 6.2
software (BD Biosciences), and data were analyzed using
FlowJo 8.7.3 software (Tree Star Inc., Ashland, OR,
USA). The isotype controls were used to set the gates
for positive and negative populations.
Stimulation experiments
Primary FLSs from one OA patient were seeded into com-
plete DMEM in triplicates in six-well plates (100,000 cells/
well) and incubated until confluence. The cells were
serum-starved in DMEM supplemented with 2% heat-
inactivated foetal calf serum for 6 hours before the differ-
ent human recombinant cytokines were added: 10 ng/ml
TNFa (Sigma), 1 ng/ml IL-1b and 1 ng/ml TGF-b1 (R&D
Systems, Minneapolis, MN, USA). The cells were har-
vested by trypsinisation after 12, 24 and 48 hours, and
podoplanin expression was measured using flow cytometry
with antipodoplanin antibody (clone D2-40). The experi-
ment was repeated four times with different primary cell
cultures, including RA-FLSs, with similar results.
Statistical analysis
Differences in protein expression between the patient
groups detected by immunohistochemistry (IHC) and
flow cytometry were evaluated using the Mann-Whitney
nonparametric test.
Results
Podoplanin is expressed in the human synovial lining
layer in RA
By carrying out IHC on paraffin sections of human
synovia, we found that podoplanin was highly expressed
in rounded cells of the epithelium-like synovial lining
layer in 17 of the 18 RA specimens (Figures 1A-D and
1L-M). In most cases, the podoplanin staining covered
the whole cell surface and was continuous along and
throughout the lining layer. Podoplanin expression was
most pronounced in areas with strong hyperplasia and
disrupted synovial architecture (Figures 1C, 1D and 1L),
staining not only the surface of all the lining layer cells
with high intensity but also adjacent interstitial cells of
the sublining layer (Figure 1D). The podoplanin expres-
sion was prominent in long cytoplasmatic processes and
was maintained on rounded, dispersed and disaggre-
gated cells in “invasive” areas (Figure 1C). Podoplanin
stained lymph vessels in all tissues (Figure 1J). The
synovium in OA was predominantly negative (Figures
1F and 1N), but single positive cells or a limited group
of them were occasionally found in the lining layer (Fig-
ures 1E and 1H). Discrete staining was sometimes
detected on the apical surface of the outermost lining
layer (Figure 1G, arrowhead). The mean score of podo-
planin expression in the synovium of the RA specimens
was 2.61 (SEM, 0.18) versus 0.33 (SEM, 0.17) for OA
specimens (P < 0.0001) (Figure 1K). The subsynovial
connective tissue in OA was negative in all cases.
To verify that podoplanin is expressed in human syno-
vial tissue in RA and to evaluate the specificity of the
antipodoplanin antibody, extracted membrane proteins
from synovial tissue samples from two RA patients were
subjected to SDS-PAGE and Western blot analysis using
D2-40 monoclonal antibody. The Western blot analysis
showed one distinct band of about 45 kDa (Figure 2) in
both samples. The antibody also recognised the recom-
binant immature podoplanin core protein (13.4 kDa
according to the manufacturer) as a band of estimated
molecular weight of about 18 kDa. The lung fibroblast
cell line MRC-5, shown by us not to express podoplanin
by flow cytometry, was used as a negative control.
Podoplanin is expressed on cadherin-11-positive
synoviocytes of the lining layer in RA
To identify which type of synoviocyte express podopla-
nin, we performed IHC and double-immunofluorescence
(double-IF) on human RA synovium using different cellu-
lar markers. We found that the fibroblast marker CD90
was expressed by interstitial cells, typically forming sheet
structures around capillaries, of the synovial sublining in
frozen sections of human synovium (Figure 3B).
However, the lining layer was CD90-negative (in contrast
to podoplanin) (Figure 3A). Both podoplanin and
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sections of RA synovia (Figure 3C and 3D). Double-IF
staining and confocal microscopy confirmed a colocaliza-
tion of cadherin-11 and podoplanin on the cellular level
of lining cells (Figure 3E). The cadherin-11 expression in
RA, compared with OA, was increased both in the lining
and in the sublining layers, especially in areas with hyper-
plasia (Figure 1L). Double-staining for podoplanin and
the macrophage marker CD68 clearly did not show any
colocalization (Figure 3F). CD68-positive cells were dis-
persed in the lining layer and in the sublining tissue in
both RA and OA.
a-sma is upregulated in podoplanin-expressing synovial
lining layer cells
Next, we were interested to see whether podoplanin
could be involved in EMT-like transdifferentiation of
RA-FLSs. We therefore investigated the expression of a-
sma and E-cadherin in relation to podoplanin in RA
synovia. We found that a-sma was expressed in the
cytoplasm of podoplanin-positive synovial lining cells in
hyperplastic areas (Figure 3I). In addition, a-sma was
expressed in vessel walls and on a few dispersed cells in
the sublining. E-cadherin could be detected in some
areas of the synovial lining layer in both RA and OA
specimens. Interestingly, the expression of E-cadherin
was very low or absent in podoplanin-expressing lining
layer cells (Figure 3G and overview in Figure 3H).
Different MMPs (especially MMP-1, MMP-3, MMP-9
and MMP-13) are upregulated in the RA synovium and
are responsible for the degradation of ECM and carti-
lage [5,38]. We used MMP-9 as an indicator of inflamed
synovium and of the presence of matrix degradation.
MMP-9 is reportedly expressed in synovial lining cells,
in leukocytes and in endothelia of the RA synovium
[39]. In agreement with this, we found high expression
of MMP-9 in the synovial lining, in sublining ectopic
lymphoid structures and in vessels in RA synovial tissue
(Figure 3J). Double-staining of podoplanin and MMP-9
showed that the podoplanin-positive lining layer cells
expressed MMP-9 (Figure 3J).
Podoplanin is expressed in cultured CD90-positive FLSs
To characterise podoplanin expression on the cellular
level, we established primary FLS cultures from both RA
(RA-FLSs) and OA (OA-FLSs) synovial specimens. At
Figure 1 Podoplanin is expressed in human synovial tissue in RA. Immunohistochemistry (IHC) of human synovial tissue from (A-D, I)
rheumatoid arthritis (RA), (E-H, J) osteoarthritis (OA) (A-D, E-H, J) using antipodoplanin antibody (D2-40) or (I) mouse immunoglobulin G1. (J)
Positive control showing lymph vessels (arrow). (K) IHC staining score of podoplanin on human synovial tissue from 18 RA and 9 OA patients.
Double immunofluorescence staining of (L and M) RA and (N) OA synovium using antipodoplanin (green) and anti-cadherin-11 (red) antibodies.
Note the extensive hyperplasia of the podoplanin-positive lining layer cells (C and D, L) and the podoplanin-positive lymph vessel (arrowhead in
N) but negative lining layer in OA (N). L, lumen. ***statistical significance P < 0,0001.
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confocal microscopy, we found that the primary FLSs
had a typical cultured fibroblast phenotype with promi-
nent stress fibres and that approximately 50% of the
FLS cells expressed podoplanin (Figure 4A and 4B). The
podoplanin expression was most pronounced in areas of
focal attachment and in small membrane protrusions
(microspikes) (Figure 4A, arrowheads).
The podoplanin expression was further evaluated in
six RA-FLS and five OA-FLS primary cell cultures using
flow cytometry, showing an average expression of 52 ±
24% and 64 ± 6%, respectively. The variation in RA-FLS
compared to OA-FLS was evident. Furthermore, 99 ±
Figure 2 Anti-podoplanin antibody D2-40 recognizes 45kD
band in Western blot of synovial protein extracts. Western blot
of extracted membrane proteins from human synovial tissue from a
patient with rheumatoid arthritis (RA) (lane 1), cell pellet of human
MRC-5 lung fibroblast cell line (lane 2) and recombinant immature
podoplanin core protein (lane 3) separated on a 20% sodium
dodecyl sulphate polyacrylamide gel electrophoresis gel probed
with the antipodoplanin antibody (D2-40).
Figure 3 Podoplanin is expressed in FLS in areas of synovial
transformation. Immunohistochemistry of (A and B) frozen and
(C-J) paraffin-embedded human synovial tissue from patients with
rheumatoid arthritis (RA) using antibodies against (A and C)
podoplanin (D2-40), (B) CD90 (AS02) and (D) cadherin-11 (3B2H5)
(arrowhead). Double immunofluorescence staining analysed by
confocal microscopy showing, in green, (E) podoplanin 18H5 and
(F-J) podoplanin D2-40, and in red, (E) cadherin-11 (3B2H5), (F)
CD68 (KP1), (G and overview in H) E-cadherin (H-108), (I) a-smooth
muscle actin (a-sma) (PA1-37024) and (J) matrix metalloproteinase 9
(MMP-9). (E) Note colocalization of podoplanin and cadherin-11
(arrowhead). L, lumen.
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Immunofluorescence staining of primary rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) showing podoplanin (red) and actin stress
fibres (green). Note accumulated podoplanin staining in membrane protrusions (arrowheads). (B) Magnification of podoplanin-positive RA-FLS. (C
and D) Flow cytometry (FACS) of primary FLS cultures from patients with RA (filled bars) and patients with osteoarthritis (OA) (striped bars)
showing the percentage of positive cells of viable cell populations using (C) antipodoplanin and phenotype markers (CD90, CD68 and CD29)
and (D) cadherin-11 antibodies. (E) Immunocytochemistry of an aggressively growing RA-FLS culture using antipodoplanin antibody. Note the
dendritic phenotype with long cytoplasmatic protrusions. (F) Representative flow cytometry plot of primary RA-FLS stained for podoplanin and
a-smooth muscle actin (a-sma) showing the double-positive population (podoplanin
+ and a-sma
+) of 58.2% in the upper right quadrant. (G)
Graph showing the percentage of podoplanin-positive primary FLS by flow cytometry at baseline, 24 and 48 hours of stimulation with control
(complete medium) (open circles), 10 ng/ml tumour necrosis factor (TNF)-a (filled squares), 1 ng/ml interleukin (IL)-1b (open diamond) and 1 ng/
ml transforming growth factor b receptor 1 (TGF-b1) (filled triangles), respectively, of a representative culture. The experiment was run in
triplicate and repeated four times using different OA-FLS and RA-FLS cultures, which showed similar results but starting at different baseline
levels of podoplanin expression.
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less than 0.6 ± 0.5% of RA-FLSs expressed the macro-
phage marker CD68. A percentage of 95 ± 0.7% OA-
FLS expressed CD90, 98 ± 1% expressed CD29 and less
than 0.8 ± 0.4% expressed CD68 (Figure 4C). The mean
expression of cadherin-11 was low in OA-FLSs (2.3%)
and slightly increased in RA-FLSs (up to 21%) (Figure
4D). Interestingly, one RA-FLS cell line had a more den-
dritic phenotype (Figure 4E) and was growing without
contact inhibition. This cell line had a 100% expression
of podoplanin on the basis of flow cytometry.
Cultured fibroblasts upregulate a-sma (up to 100% by
passage 5) in culture [40,41]. We were interested to see
whether this is true also for primary FLSs. Using flow
cytometry, we found that nearly 100% of both OA-FLSs
and RA-FLSs express a-sma by passage 6. About 60%
(58.2% for RA-FLSs and 61.7% for OA-FLSs) were dou-
ble-positive for podoplanin and a-sma. All podoplanin-
positive cells expressed a-sma (Figure 4F).
Podoplanin expression in vitro is increased by
proinflammatory cytokines
IL-1b and TNFa are known to activate RA-FLSs. TGF-
b1 is a key mediator of EMT and promotes the differen-
tiation of fibroblasts into myofibroblasts in wound heal-
ing and fibrosis.
In this study, we investigated the effects of IL-1b,
TNFa and TGF-b1 stimulation on podoplanin expres-
sion in primary FLSs. We found a more than twofold
increase in podoplanin expression in OA-FLS culture
after stimulation with 1 ng/ml IL-1b and 10 ng/ml
TNFa. This culture had a low baseline expression of
podoplanin (30%), which increased to 72% after 48
hours of IL-1b stimulation (Figure 4G). Using two dif-
ferent primary RA-FLS cultures, we found an early
increase in podoplanin expression from, on average, 50%
at baseline to about 90% after 12 hours of IL-1b stimu-
lation. These effects were maintained after 36 hours of
stimulation (data not shown). TGF-b1( 1n g / m l )h a da
moderate effect (+1.7-fold) on podoplanin expression
evident at late time points (48 hours) (Figure 4G).
Discussion
In this study, we have shown that the tumour-associated
proinvasive glycoprotein podoplanin is highly expressed
in synovial lining layer cells in RA but is rarely found in
OA synovial specimens. The expression of podoplanin
was most pronounced in areas with signs of inflamma-
tion (that is, the presence of leukocyte infiltrates and
ectopic lymphoid structures) and synovial transforma-
tion (indicated by lining layer hyperplasia, MMP-9
expression and upregulation of cadherin-11 and a-sma).
Furthermore, the podoplanin-expressing lining layer
cells expressed cadherin-11 but not the macrophage
marker CD68, suggesting that these synoviocytes were
FLSs rather than synovial macrophages.
All included RA patients had progressed to erosive
disease (Larsen index score >1), and all except one had
a high podoplanin expression score (IHC score >1) of
the synovial tissue from the replaced joint (Table 1).
However, without the rarely available tissue specimens
from nonerosive and early RA joints to compare these
tissues with, we could not analyze whether there is a
correlation between erosive disease and podoplanin
expression.
The function of podoplanin is far from elucidated. On
one hand, this small glycoprotein is constitutively
expressed on the apical surface of lymph endothelia as
well as on specialised epithelia (for example, podocytes)
facing fluid compartments [28,42,43]. On the other
hand, podoplanin is crucial for processes involving cell
migration, such as the specific embryologic development
of deep lymphatics [28] and the invasion and metastasis
of certain tumour cells or tissues [32]. Podoplanin has
been shown to bind ezrin, an actin filament membrane
linker protein, on the inside of the cell in vitro [30,44].
It has therefore been suggested that podoplanin is
involved in directing actin polymerisation, thereby form-
ing the cellular protrusions needed for migration.
In our study, the marked and widespread expression
of podoplanin in lining layer cells in RA was not
restricted to the apical cell surface. Instead, it resembled
the strong whole cell surface-staining pattern of podo-
planin in tumour tissues [30]. It has been shown that
RA-FLSs of highly inflammatory synovial tissue show a
gene expression profile characteristic of myofibroblasts
[23]. We detected coexpression of podoplanin and a-
sma of FLSs in areas of synovial transformation and
found that the expression of E-cadherin was low or
absent in the podoplanin-expressing lining layer cells.
We know from earlier studies that podoplanin can pro-
mote EMT of epithelial Madin-Darby canine kidney
cells in vitro [44]. EMT is a biologic process in which
polarised epithelial cells undergo sequential changes into
a mesenchymal cell phenotype with increased migratory
potential and the production of ECM components [24].
Loss of E-cadherin and gain of a-sma expression consti-
tute examples of such changes. We therefore hypothe-
sise that podoplanin is involved in an EMT-like
transdifferentiation of RA-FLSs into myofibroblasts.
Podoplanin has been observed in interstitial fibroblasts
in different inflammatory environments in vivo and in
vitro [33,34]. In agreement with this observation, we
found a locally increased expression of podoplanin in
interstitial cells of the sublining connective tissue in spe-
cimens from patients with RA. However, it is difficult to
determine whether upregulated podoplanin expression
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general inflammation or whether this phenomenon was
part of a specific activation and transdifferentiation of
FLSs in RA.
To confirm the specificity of the D2-40 antibody and
the expression of podoplanin in RA synovial tissue, we
performed SDS-PAGE and Western blot analysis of pro-
tein extracts showing a distinct band of about 45 kDa.
The mature glycosylated form of podoplanin has been
estimated to be about 38 to 40 kDa [27]. The difference
in approximated molecular weight could be explained
by the reported heterogeneity of podoplanin in SDS-
PAGE, which arises as a result of heavily O-linked glyco-
sylation of the core protein [27] as well as a slightly
unspecific migration of the used molecular weight
markers.
Characteristics of RA are the phenotypic changes and
hyperplasia of FLSs of the lining layer. Conventional iso-
lation of FLSs from synovial tissue yields homogeneous
fibroblast cultures [45], but the interindividual morpho-
logical variation is large, and cultures presumably arise
from both the synovial lining and sublining layers.
We established primary cultures of FLSs from human
synovial tissues by enzyme digestion and found that
the cells had typical fibroblast morphology. Nearly all
of the primary FLSs stained positive for the fibroblast
marker CD90/Thy-1 and most expressed b1 integrins.
However, the IHC staining of human synovia using the
anti-CD90 antibody revealed positive expression in the
sublining, but not in the lining layer cells (Figures 3A
and 3B). Fibroblasts possess a remarkable phenotypic
plasticity [41] as well as a positional identity [46]. The
synovium (lining layer versus sublining layer) of both
healthy and RA patients harbour phenotypically differ-
ent (by morphology and expression of surface markers)
populations of fibroblasts. CD90 might therefore be a
good marker for interstitial tissue fibroblasts, but not
for the FLSs forming the epithelium-like lining of the
synovium. In addition, fibroblasts change the expres-
sion of several surface molecules in vitro and acquire
an “active” phenotype with prominent stress fibres and
focal adhesions [47] when cultured on plastic. We
therefore concluded that most of the established pri-
mary FLS cultures in this study originated from the
sublining connective tissue or acquired a sublining
fibroblast phenotype (with respect to CD90 expression)
in culture. Using IHC, we found that cadherin-11 was
expressed both in the lining layer and in cells of the
sublining tissue in reactive areas, but when using flow
cytometry, we found it on average in only 10% of the
isolated primary FLSs. These data support the assump-
tion that the isolated primary FLSs in these experi-
ments originated from the sublining rather than from
the lining layer.
Fibroblasts have been shown to upregulate podoplanin
in culture [34]. In this study, we did not observe any
significant difference in mean podoplanin expression
between the RA-FLS and OA-FLS cultures. Only one
culture, derived from an RA patient, was growing with-
out contact inhibition, a characteristic of activated FLSs
in RA. All cells of this culture were expressing podopla-
nin. Taken together, our results suggest that cultures of
the lining layer FLS phenotype are hard to establish by
using this technique and that primary FLSs, like other
fibroblasts, probably upregula t ep o d o p l a n i ni nc u l t u r e .
The observed upregulated expression of a-sma of the
primary FLSs constitutes another example of an
acquired feature of cultured fibroblasts.
Finally, we found a more than twofold increase in podo-
planin expression in primary FLSs after stimulation with
IL-1b and TNFa compared with controls. Interestingly,
we also detected an increase in podoplanin expression in
response to TGF-b1 stimulation. TGF-b1 is a key media-
tor of EMT and promotes the differentiation of fibroblasts
into myofibroblasts in wound healing and fibrosis.
Furthermore, TGF-b1-induced podoplanin in human
fibrosarcomas [48] was found to be increased in arthritic
joints in RA [49] and promoted EMT of FLS in vitro [13].
The fact that proinflammatory cytokines and growth fac-
tors, known to be present in high concentrations in the
RA joint, stimulate podoplanin expression in primary FLSs
in vitro supports our finding that podoplanin is upregu-
lated in the synovium of RA patients and might be
involved in the transdifferentiation of FLSs in RA.
Conclusions
We can now add podoplanin expression as a shared char-
acteristic of activated RA-FLSs and tumour cells that pos-
sibly affects common features of RA and carcinoma-like
fibrotic tissue transformation and tissue invasion. Podo-
planin might therefore be an important target not only in
cancer therapy but also in the treatment of RA.
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